Doxorubicin is a classical but useful anti-tumor agent. It is used for the treatment of a variety of malignancies including solid tumors and leukemia due to its broad spectrum anti-tumor activity. It also has well known toxic side effects that must be minimized for its successful use clinically. This book discusses intraperitoneal doxorubicin; preclinical characterization of the drug-delivery device DCBeads for transarterial chemoembolization of doxorubicin and nemorubicin; doxorubicin-induced cardiomyopathy; advanced therapies of doxorubicin by carrier of drug delivery system or combined food components; and prevention and management of cariotoxicity.